Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Thoracic 1Sarcoma 1Dermatologic 1CNS 1

Conditions

Glioblastoma 157Brain Neoplasms 98Glioma 69Gliosarcoma 43Astrocytoma 30Carcinoma, Non-Small-Cell Lung 19Recurrence 18Oligodendroglioma 18Central Nervous System Neoplasms 16Neoplasms 14Meningeal Carcinomatosis 10Ependymoma 10Meningioma 7Neurofibromatosis 2 6Neuroblastoma 6Melanoma 6Diffuse Intrinsic Pontine Glioma 6Neuroma, Acoustic 5Medulloblastoma 5Lung Neoplasms 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neurologic Manifestations 4Colorectal Neoplasms 4Breast Neoplasms 4Spinal Cord Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Radiotherapy 6Temozolomide 5Flow Cytometry 5Cyclophosphamide 5Therapeutics 4Psychiatric Rehabilitation 4Melphalan 4Magnetic Resonance Spectroscopy 4Filgrastim 4sargramostim 3Specimen Handling 3Polymerase Chain Reaction 3Methylprednisolone 3liposomal amphotericin B 2Topotecan 2Thiotepa 2Rituximab 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Itraconazole 2Immunologic Techniques 2Fentanyl 2Early Intervention, Educational 2Dexamethasone 2Caspofungin 2Carmustine 2Calcium Dobesilate 2Busulfan 2Aprepitant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Bevacizumab × CNS × Clear all
NCT01954030 2016-02-19

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Duke University

Phase 1 Terminated
17 enrolled
CNSLymphoid

Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡